公开(公告)号：US20180306791A1

公开(公告)日：2018-10-25

申请号：US15771622

申请日：2016-10-28

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： Danton BOUNDS ,  Jenny L. CRAIGEN ,  William E. FIELES ,  Fiona M. GERMASCHEWSKI ,  Gaelle HERLEDAN ,  Lydia LEE ,  Patrick A. MAYES ,  Lee MCCAHON ,  Katherine (NEE SULLY) NEVIN ,  Jennifer PATERSON ,  Manuel RODRIGUEZ-JUSTO ,  Laura M. SEESTALLER-WEHR ,  James TUNSTEAD ,  Kwee L. YONG

IPC: G01N33/574 ,  G01N33/50 ,  G01N15/14 ,  A61P35/00

CPC classification number: G01N33/57407 ,  A61P35/00 ,  C07K16/2878 ,  G01N15/14 ,  G01N33/5091 ,  G01N2333/70578 ,  G01N2800/52

Abstract: Methods are provided for determining prognosis of multiple myeloma in a patient by measuring expression of BCMA in a sample. Also provided are methods for treating multiple myeloma by measuring expression of BCMA in a sample and administering an effective amount of an antigen binding protein that binds BCMA. Also provided are kits for measuring BCMA expression in a sample.

公开(公告)号：US20200181275A1

公开(公告)日：2020-06-11

申请号：US16620782

申请日：2018-06-08

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Inventor： Christopher B. HOPSON ,  David J. KILIAN ,  Patrick A. MAYES ,  Sapna YADAYILLI ,  Niranjan YANAMANDRA

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00

Abstract: The present invention provides methods of treating cancer in a patient in need thereof, the method comprising administering to the patient an effective amount of an agent directed to human ICOS and an effective amount of an agent directed to human OX40 sequentially. The present invention also provides an anti-ICOS antibody or antigen binding fragment thereof and an anti-OX40 antibody or antigen binding fragment thereof for sequential use in treating cancer in a human in need thereof.

公开(公告)号：US20190256608A1

公开(公告)日：2019-08-22

申请号：US15780331

申请日：2016-12-01

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： Patrick A. MAYES ,  Laura M. SEESTALLER-WEHR ,  Lyuben TSVETKOV ,  Niranjan YANAMANDRA ,  Jingsong YANG

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: Disclosed herein are combinations of an antigen binding protein that binds BCMA with a antigen binding protein that bind to an immunomodulatory agents, such as PD-1 or OX40, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combinations, including uses in cancer.